Tobin Schilke - 20 Jan 2023 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
20 Jan 2023
Net transactions value
-$31,000
Form type
4
Filing time
23 Jan 2023, 16:35:36 UTC
Previous filing
10 Jan 2023
Next filing
02 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Sale $31,000 -1,000 -1.7% $31.00 57,877 20 Jan 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke.
F2 Includes 3,716 shares purchased pursuant to the Issuer's 2014 Employee Stock Purchase Plan.